Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) traded down 6.4% during mid-day trading on Friday . The company traded as low as $64.56 and last traded at $64.65. 630,416 shares traded hands during trading, a decline of 5% from the average session volume of 664,786 shares. The stock had previously closed at $69.04.

A number of equities research analysts have issued reports on the stock. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Friday, March 15th. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Cowen reiterated a “buy” rating and set a $69.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, February 26th. Raymond James reiterated an “outperform” rating and set a $80.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, February 22nd. Finally, Citigroup increased their target price on shares of Ultragenyx Pharmaceutical from $54.00 to $62.00 and gave the stock a “neutral” rating in a report on Thursday, February 21st. Six research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. Ultragenyx Pharmaceutical has a consensus rating of “Buy” and a consensus price target of $76.16.

The stock has a market cap of $3.54 billion, a P/E ratio of -8.75 and a beta of 2.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, February 19th. The biopharmaceutical company reported ($1.73) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.74) by $0.01. Ultragenyx Pharmaceutical had a negative net margin of 383.75% and a negative return on equity of 35.26%. The company had revenue of $16.26 million for the quarter, compared to the consensus estimate of $13.30 million. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical Inc will post -6.79 EPS for the current fiscal year.

In other Ultragenyx Pharmaceutical news, CFO Shalini Sharp sold 14,800 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $70.00, for a total value of $1,036,000.00. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 8.40% of the company’s stock.

Several large investors have recently made changes to their positions in the business. Alliancebernstein L.P. grew its position in shares of Ultragenyx Pharmaceutical by 5.4% in the 3rd quarter. Alliancebernstein L.P. now owns 992,357 shares of the biopharmaceutical company’s stock valued at $75,757,000 after buying an additional 50,489 shares during the last quarter. Capital Impact Advisors LLC grew its position in shares of Ultragenyx Pharmaceutical by 31.7% in the 4th quarter. Capital Impact Advisors LLC now owns 37,858 shares of the biopharmaceutical company’s stock valued at $1,585,000 after buying an additional 9,112 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Ultragenyx Pharmaceutical by 5.3% in the 3rd quarter. Wells Fargo & Company MN now owns 23,742 shares of the biopharmaceutical company’s stock valued at $1,812,000 after buying an additional 1,194 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $1,954,000. Finally, Kiwi Wealth Investments Limited Partnership purchased a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $958,000. 97.80% of the stock is currently owned by institutional investors.

WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2019/03/22/ultragenyx-pharmaceutical-rare-shares-down-6-4.html.

About Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Featured Article: Blue-Chip Stocks

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.